Current Research Studies

A Phase III Randomized Placebo-Controlled Study to Examine the Efficacy and Safety of DAS 181 for the Treatment of Lower Respiratory Tract Parainfluenza Infection in Immunocompromised Subjects

DAS181

Condition(s): Other
Clinicaltrials.gov ID: NCT03808922

What is the goal of the study?

This is a multi-center, randomized, double-blind, placebo-controlled Phase III study to investigate the efficacy and safety of DAS181 for the treatment of immunocompromised subjects diagnosed with lower respiratory tract infection (LRTI) due to a sialic-acid dependent respiratory virus (SAD-RV), with particular emphasis on parainfluenza (PIV).

Who can participate in the study?

Please contact the study team listed below to learn more.

Study Team:

PI (Study Doctor): Alpana Waghmare
Study Team Member: Jamie Costales, Jamie.Costales@seattlechildrens.org

Seattle Children’s complies with applicable federal and other civil rights laws and does not discriminate, exclude people or treat them differently based on race, color, religion (creed), sex, gender identity or expression, sexual orientation, national origin (ancestry), age, disability, or any other status protected by applicable federal, state or local law. Financial assistance for medically necessary services is based on family income and hospital resources and is provided to children under age 21 whose primary residence is in Washington, Alaska, Montana or Idaho.